Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human cytomegalovirus glycoprotein H (gH, encoded by the UL75 gene) is a viral envelope protein essential for HCMV entry into host cells[6][7]. gH functions as part of a dimeric complex with glycoprotein L (gL), which in turn forms larger complexes—the gH/gL/gO trimer and the gH/gL/UL128-131 pentamer—each mediating entry into different cell types[6][7][8]. gH is required for membrane fusion, collaborating with glycoprotein B (gB), and is recognized by neutralizing antibodies, making it a principal target for vaccine and monoclonal antibody development[6][7][8][1]. Variants of the gH gene (notably gH1 and gH2) exist, and gH's role in viral entry, cellular tropism, and immune evasion underpins its status as a central therapeutic and diagnostic target in CMV infection[6][7][8][1][9].
Neutralizing antibodies prevent cell entry by binding to glycoprotein H or its complexes (gH/gL/gO trimer, gH/gL/UL128-131 pentamer), blocking fusion and viral attachment
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human cytomegalovirus glycoprotein H (gH).